Nanotechnology-Based Biosensors and Diagnostics: Technology Push versus Industrial/Healthcare Requirements

Nanoparticles-Based Naked-Eye Colorimetric Immunoassays for In Vitro Diagnostics

“…On the other hand, the last decade has witnessed continuous improvement in immobilization chemistries, immunoassay formats and bioanalytical platforms, which have led to significant advances in the field of immunoassays. These advances have been supplemented by the rapidly evolving technology and business trends towards smart phone-based POC devices for immunoassays [7]. NP-based naked-eye immunoassays will certainly play a pivotal role in the development of cost-effective point-of-care IVD in the near future based on their superior analytical performance, novel characteristic features and plethora of applications.…”

Carbon nanotubes part II: a remarkable carrier for drug and gene delivery

“…There has been a huge technology push, leading to the development, successful testing and even clinical approval of several different kinds of nanocarriers. However, there is still a significant lag in their commercialization, especially due to the lack of international regulatory guidelines for evaluating the safety of NMs and growing public concern about their toxicity [3]. …”

Recent advances in electrochemical biosensing schemes using graphene and graphene-based nanocomposites

“…However, further efforts are desired in order to test the cytotoxicity for a relatively longer period of time. But such tasks require the development of standard international guidelines for the determination of cytotoxicity of nanomaterials as the lack of such information often results in highly conflicting reports [421].…”